Many groups are affected by breast cancer, the most common type of cancer in Brazil and around the world. As we enter the new year, Brazil expects a significant increase in new breast cancer cases, with many patients diagnosed with advanced stages. This portrays the important role of neoadjuvant chemotherapy (NAC), which aims to contract tumors before surgical removal. The success of NAC, especially in the acquisition of a pathological complete response state (PCR) (without cancer traces after treatment) is a key focus. Research shows that achieving PCR is associated with better survival regardless of cancer subtype. However, the true effectiveness of these treatments in daily, especially in populations that are not usually included in clinical trials, remains a key area of research. The study explores the field, using real-world data to evaluate treatment patterns and outcomes for a wider group of patients, including those who are usually excluded from clinical trials.
The study was carefully curated by Professor Marcelo Antonini and Dr. Gabriel Duque Pannain of the Hospital, Do Servidor Público lens Francisco Morato de Oliveira; Dr. André Mattar, Marina Diogenes Teixeira Dr. Andressa Gonçalves Amorim and Dr. Luiz Henrique Gebrim of Women’s Health Hospital; Dr. Fernanda Grace Bauk Richter of Do Ipiranga Hospital; Professor Juliana Monte Real and Reginaldo Coelho Guedes Lopes is also the hospital’s Público lens Francisco Morato de Oliveira, known for its thorough and organized approach. The team carefully collected and reviewed data from women with non-breast cancer who received NAC. This detailed analysis in the Breast Journal involves a retrospective study of patient records, focusing on treatment outcomes and survival probability.
Professor Antonini explained: “Our study included a large number of patients diagnosed with non-breast cancer and treated with NAC. We carefully tracked the rate at which complete cancers disappeared after NAC and carefully examined their continued health for overall health. and no disease presence impact. “This approach allows for a comprehensive understanding of the treatment efficiency of various patient groups.
The core purpose of this study was to evaluate the rate of PCR and its impact on overall and disease-free survival. The researchers found that considering the diversity of breast cancer, a large percentage of patients received PCR, which is a noteworthy observation. This difference is particularly noteworthy in patients with HER-2-positive tumors receiving trastuzumab, a specific targeted therapy.
“Complete cancer disappearance in breast cancer type and its prognostic value differences. In our study, achieving complete cancer disappearance can be seen as a sign of favorable clinical outcomes because it is associated with persistent health and disease-free presence. ” Professor Antonini said. This observation is crucial to understand the differential effects of NAC.
In terms of survival analysis, studies show that patients who received PCR are more likely to be healthy and disease-free for five years than those who did not achieve PCR. A similar pattern was observed in the disease-free presence rate, highlighting the prognostic significance of PCR in treatment.
This study is particularly important for the environment in the real world and provides insights beyond the controlled environment of clinical trials. It highlights the role of PCR as a potential marker for predicting treatment outcomes in patients with NAC breast cancer.
Conclusions Professor Anthony Ni stressed that “patients who have sustained health and disease-free presence within five years have significantly higher chances of sustained health and disease-free presence within five years than groups that have not reached this state.” Sexual statements highlight the correlation between PCR and improved survival outcomes. The research of Marcelo Antonini and his team has made an important contribution to the field of oncology, especially for healthcare professionals in Brazil and around the world. It emphasizes the importance of personalized treatment strategies and the role of PCR as an alternative marker of clinical outcomes in breast cancer treatment.
Journal Reference
Marcelo Antonini, André Mattar, Fernanda Grace Bauk Richter, etc. “Real-world evidence of neoadjuvant chemotherapy for breast cancer treatment in a Brazilian multicenter cohort: Correlation of pathological complete response with overall survival,” The Breast, 2023. DOI: https://doi.org/10.1016/j.breast.2023.103577 .
About the Author
Dr. Marcelo Antonini He is the host of the breast surgery medical residence program of São Paulo/Brazil doctor Público lens. Doctor of Health Sciences. Professor at Santo Amaro University (UNISA) and the University of Sao Paulo (Unicid).
